|
Re: RVX 2023 valuation attempt using Moderna metrics
|
11
|
Resverlogix Corp.
|
Jan 30, 2022 12:28PM
|
|
CityNews cover
|
9
|
Resverlogix Corp.
|
Jan 31, 2022 09:20AM
|
|
Re: By the time….
|
10
|
Resverlogix Corp.
|
Mar 02, 2022 12:52PM
|
|
Re: Study results?
|
5
|
Resverlogix Corp.
|
Mar 07, 2022 11:56AM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
6
|
Resverlogix Corp.
|
Apr 05, 2022 12:07PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
8
|
Resverlogix Corp.
|
Apr 05, 2022 01:56PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
8
|
Resverlogix Corp.
|
Apr 05, 2022 06:04PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
5
|
Resverlogix Corp.
|
Apr 05, 2022 06:13PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
7
|
Resverlogix Corp.
|
Apr 05, 2022 08:13PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
9
|
Resverlogix Corp.
|
Apr 06, 2022 08:48AM
|
|
Long COVID symptoms linked to inflammation
|
9
|
Resverlogix Corp.
|
Jun 28, 2022 06:06PM
|
|
Epigenetics and Aging: The effects of DNA breakage and repair
|
3
|
Resverlogix Corp.
|
Jan 28, 2023 09:44PM
|
|
"...quite remarkable... 1 year experiment of age reversing with epigenetics..."
|
1
|
Resverlogix Corp.
|
Feb 03, 2023 10:42AM
|
|
Re: Long Covid
|
5
|
Resverlogix Corp.
|
Jan 22, 2024 10:37AM
|
|
Re: Long Covid
|
6
|
Resverlogix Corp.
|
Jan 22, 2024 03:23PM
|
|
Re: Long Covid
|
5
|
Resverlogix Corp.
|
Jan 22, 2024 03:40PM
|
|
Re: Long Covid
|
2
|
Resverlogix Corp.
|
Jan 22, 2024 06:07PM
|
|
Re: Response
|
2
|
Resverlogix Corp.
|
Jan 23, 2024 12:59PM
|
